CommercialCoverageMedium impact
11.14.06j, Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)
Independence Blue Cross·Orthopedics, Sports Medicine·Medical Policy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
Independence Administrators reissued their policy on Autologous Chondrocyte Implantation (ACI) and other cell-based treatments for focal articular cartilage lesions. This policy update affects coverage criteria and billing requirements for these specialized orthopedic procedures used to treat cartilage damage in joints.
Action Required
By June 10, 2026: Billing team must review the updated ACI policy to understand any changes to coverage criteria, prior authorization requirements, or documentation standards for autologous chondrocyte implantation procedures. Update billing protocols and provider guidelines accordingly to ensure compliance with Independence Administrators requirements.